Skip to main content
Premium Trial:

Request an Annual Quote

Abbott Gets FDA Emergency Use Authorization for Monkeypox PCR Test

NEW YORK — The US Food and Drug Administration said Friday it has granted Emergency Use Authorization for Abbott's real-time PCR monkeypox test, the Alinity m MPXV assay.

The test is for use by CLIA-certified laboratories for the detection of monkeypox virus DNA from lesion swab samples. In its authorization letter, the FDA noted that monkeypox virus DNA is generally detectable in human pustular or vesicular lesion specimens during the acute phase of infection.

The assay can be used on Abbott's Alinity m instrument or other authorized instruments, which perform sample preparation, PCR assembly, amplification, detection, and result calculation and reporting, the FDA said, adding it requires use of the Alinity m MPXV CTRL Kit.

The US Department of Health and Human Services declared a state of emergency on Aug. 9 in response to outbreaks with the virus within the United States. Quest Diagnostics received the first EUA for its Monkeypox Virus Qualitative Real-Time PCR test, which detects monkeypox and other non-variola orthopoxvirus DNA in lesion swab specimens.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.